Oxcarbazepine
Product Images NDC 81033-113

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 81033-113). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kesin Pharma, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

81033-113-05 Foil Label (81033 113 05)

81033-113-05 Foil Label (81033 113 05)
This text provides details about a medication delivered in 5mL containing 300mg per 5mL of Oxcarbazepine oral suspension. The product should be stored between 59°F and 86°F and has an expiration date of 10/31/2025. The package was produced by Kesin Pharma in Oldsmar, FL. It mentions "Sugar-Free" and that it is for oral use only.*
FDA Label Image

81033-113-30 Case Pack (81033 113 30)

81033-113-30 Case Pack (81033 113 30)
This is a description for Oxcarbazepine Oral Suspension, USP with a concentration of 300mg/5mL. The product is packaged in 30 x 300mg/5mL unit dose cups for institutional use. The medication is distributed by Kesin Pharma located in Oldsmar, FL. The expiration date is indicated as 04JUN205 and the storage temperature is recommended to be between 59°F to 86°F (15°C to 30°C).*
FDA Label Image

Structural Formula (Image01)

Structural Formula (Image01)
FDA Label Image

Figure 1 (Image02)

Figure 1 (Image02)
This text is a part of a log-rarkcres document, showing information related to Treatment Group with Oxcarbazeping and Placebo. The document also includes data on Time on Treatment from Day 1 to Day 11.*
FDA Label Image

Figure 2 (Image03)

Figure 2 (Image03)
This text refers to the measurement of seizure rate in a study comparing Oxcarbazepine to Placebo treatment groups. The statistical analysis using the Log-Rank Test resulted in a p-value of 0.048, which indicates potential significance in the difference between the two groups regarding seizure occurrence.*
FDA Label Image

Figure 3 (Image04)

Figure 3 (Image04)
FDA Label Image

Figure 4 (Image05)

Figure 4 (Image05)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.